Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VolitionRx’s NuQ® Assays Demonstrate 80% Detection Rate in Prostate Cancer

Published: Monday, March 17, 2014
Last Updated: Monday, March 17, 2014
Bookmark and Share
Study data also demonstrates ability to distinguish between prostate and colorectal cancer.

VolitionRx Limited announces data from a pilot study into the utility of VolitionRx’s NuQ® tests to diagnose prostate cancer. 

The results from the trial show that VolitionRx NuQ® assays were able to detect approximately 80 per cent of prostate cancer cases. Significantly, the trial showed that not only does the test have a high detection rate for prostate cancer, but it can differentiate between colorectal and prostate cancer. It does this by detecting the levels of epigenetically altered circulating nucleosomes in each sample, the structure of which Volition has found to be different in the two different types of cancer. For example, levels of circulating nucleosomes containing H3K9(Me)3 were elevated in colorectal cancer, but supressed in prostate cancer.  This indicates that NuQ® ELISA tests could be used to detect both prostate and colorectal cancers. 

Dr. Jake Micallef, Chief Scientific Officer at VolitionRx, will present a poster at The International Society of Oncology and Biomarkers Congress (ISOBM) in Barcelona, sharing results of the latest study into the effectiveness of NuQ® assays as an initial screening tool in detecting colorectal and now prostate cancer.  The poster abstract and a PDF of the poster is available on the VolitionRx website at: http://volitionrx.com/technologies-abstracts-papers-posters.html. 

“This is a very exciting outcome for us as we continue the development of our NuQ tests,” says Dr. Jake Micallef. “To have proof that with the right panel combination, NuQ tests can distinguish between different types of cancer as well as healthy samples, is just what we’ve been working towards. Detection of two major cancers with a blood test is a major milestone and a sound basis on which to investigate further cancers for panels of NuQ tests that detect and distinguish cancer diseases.”

NuQ® assays identify and measure circulating nucleosomes structures for the presence of epigenetic cancer signals within the blood. Results from another recent trial conducted demonstrated that the NuQ® assays were able to also detect more than 85 per cent of colorectal cancer cases with greater than 85 per cent specificity. The earlier study took samples from both healthy subjects and subjects recently diagnosed with colorectal cancer.      

Volition is carrying out several clinical trials on the effectiveness of the NuQ® assays as a cancer diagnostic tool: 

• A 4,800 patient retrospective study and an 11,000 patient prospective study into colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. 

• A 2,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany.

• A 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VolitionRx Invests in Laboratory Automation System
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial.
Wednesday, August 13, 2014
VolitionRx Extends Agreement with University Hospital Bonn to Include CE Mark Performance Evaluation
The agreement also doubles the Hospital’s prospective trial of 20 cancers, and adds a range of additional vital background work.
Thursday, April 24, 2014
VolitionRx Announces Collaboration with Wales Cancer Bank
VolitionRx Limited announces that it will commence a large internal clinical study for its Nucleosomics® diagnostic products this month.
Thursday, January 10, 2013
Scientific News
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!